News

Bayer faces potential fine over cholesterol lowering drug

BMJ 2001; 323 doi: 10.1136/bmj.323.7310.415a (Published 25 August 2001)
Cite this as: BMJ 2001;323:415.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Annette Tuffs, Heidelberg

    Bayer, the German company that was forced earlier this month to withdraw a cholesterol lowering drug from the market, might have to pay a fine of DM50000 (£16200; $23400) for withholding from the German authorities information on the drug's potentially fatal interaction with another drug.

    Bayer's drug, cerivastatin (Baycol in the United States, Lipobay in the United Kingdom), was withdrawn after 52 deaths occurred in patients taking the drug; 31 of the deaths were in the United States (18 August, p …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular